A Simplified CMV-specific T Cell Transfer Targeting Drug-resistant CMV Retinitis. (18th August 2022)

• Record Type: Journal Article
• Authors: Mo, Wenjian; Liang, Yuqin; Wang, Caixia; Zhang, Yuehong
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 6(2022)
• Page Start: 1541
• Page End: 1543
• Publication Date: 2022-08-18
• Subjects: CMV -- retinitis -- drug resistant -- immunotherapy -- severe aplastic anemia; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2021.1900876
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Background: Among severely immunosuppressed patients resistant or refractory cytomegalovirus (CMV) retinitis is not uncommon, and is potentially blinding in the affected eye. Immunotherapy using CMV-specific cytotoxic T lymphocytes (CTLs) is an emerging and promising alternative for the control of resistant or refractory CMV retinitis. However, highly purified CMV-CTLs are still not available in the majority of medical institutions in China because the generation of CMV-CTLs is labor intensive, time-consuming and expensive. Purpose: This letter describes the clinical responses to a simplified CMV-CTL immunotherapy aimed at controlling drug-resistant CMV retinitis in two immunodeficient patients. Conclusions: Our cases suggest that the simplified CMV-CTL immunotherapy offers a highly efficient and low-cost solution to drug-resistant CMV retinitis. This immunotherapy strategy targeting drug-resistant CMV retinitis is likely to be cost-effective in the context of a specific patient population.